rhuMAb2c4 (Omnitarg)
Drug timelines are a Plus or Pro feature.
1 regulatory and trial event tracked for rhuMAb2c4 (Omnitarg), covering 2015-09-30 to 2015-09-30. Get the full timeline:
Most recent: Clinical Trial Update: A Phase Ib, Open-label, Multicenter Study of the Safety and PK of the Combination of rhuMAb2c4 (Omnitarg), a Recombinant Humanized Antibody to HER2, and Capecitabine (Xeloda) in Patients With Advanced Solid Tumors [Phase 1]